PL2623497T3 - Sól megluminowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu - Google Patents
Sól megluminowa 6-fluoro-3-hydroksy-2-pirazynokarboksamiduInfo
- Publication number
- PL2623497T3 PL2623497T3 PL11829249T PL11829249T PL2623497T3 PL 2623497 T3 PL2623497 T3 PL 2623497T3 PL 11829249 T PL11829249 T PL 11829249T PL 11829249 T PL11829249 T PL 11829249T PL 2623497 T3 PL2623497 T3 PL 2623497T3
- Authority
- PL
- Poland
- Prior art keywords
- fluoro
- hydroxy
- meglumine salt
- pyrazine carboxamide
- pyrazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010221620 | 2010-09-30 | ||
PCT/JP2011/072329 WO2012043696A1 (ja) | 2010-09-30 | 2011-09-29 | 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのメグルミン塩 |
EP11829249.9A EP2623497B1 (en) | 2010-09-30 | 2011-09-29 | Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2623497T3 true PL2623497T3 (pl) | 2016-07-29 |
Family
ID=45893135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11829249T PL2623497T3 (pl) | 2010-09-30 | 2011-09-29 | Sól megluminowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu |
Country Status (19)
Country | Link |
---|---|
US (3) | US20130217708A1 (pl) |
EP (1) | EP2623497B1 (pl) |
JP (1) | JP5936546B2 (pl) |
CN (1) | CN103209967B (pl) |
CY (1) | CY1117218T1 (pl) |
DK (1) | DK2623497T3 (pl) |
ES (1) | ES2561878T3 (pl) |
HK (1) | HK1183014A1 (pl) |
HR (1) | HRP20160218T1 (pl) |
HU (1) | HUE026794T2 (pl) |
MY (1) | MY161757A (pl) |
PH (1) | PH12015501328A1 (pl) |
PL (1) | PL2623497T3 (pl) |
RS (1) | RS54642B1 (pl) |
SG (1) | SG188662A1 (pl) |
SI (1) | SI2623497T1 (pl) |
SM (1) | SMT201600184B (pl) |
TW (1) | TWI507397B (pl) |
WO (1) | WO2012043696A1 (pl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
MX2020011961A (es) | 2010-03-24 | 2022-04-19 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. |
JPWO2012043700A1 (ja) | 2010-09-30 | 2014-02-24 | 富山化学工業株式会社 | 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミドのナトリウム塩 |
SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
TWI700101B (zh) | 2014-03-24 | 2020-08-01 | 美商百歐維拉提夫治療公司 | 凍乾之因子ix調配物 |
CN104610153B (zh) * | 2015-01-19 | 2017-02-22 | 沈阳中海生物技术开发有限公司 | 奥扎格雷葡甲胺盐及其组合物、制备方法和用途 |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
WO2018003946A1 (ja) * | 2016-06-30 | 2018-01-04 | 富山化学工業株式会社 | 凍結乾燥製剤の製造方法 |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
CN111556752A (zh) * | 2017-12-28 | 2020-08-18 | 富士胶片富山化学株式会社 | 冻干制剂的制造方法 |
MX2021005691A (es) | 2018-11-19 | 2021-07-07 | Jazz Pharmaceuticals Ireland Ltd | Formulaciones de farmacos resistentes al alcohol. |
CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
CN111214446B (zh) * | 2020-03-07 | 2022-02-25 | 瑞阳制药股份有限公司 | 一种供注射用法匹拉韦l-精氨酸盐冻干制剂 |
CN114159442A (zh) * | 2020-09-11 | 2022-03-11 | 盈科瑞(天津)创新医药研究有限公司 | 法匹拉韦在制备预防或治疗冠状病毒感染性疾病药物中的应用 |
CN114159414A (zh) * | 2020-09-11 | 2022-03-11 | 盈科瑞(天津)创新医药研究有限公司 | 一种雾化吸入用法匹拉韦溶液及其制备方法 |
CN113750105A (zh) * | 2020-12-11 | 2021-12-07 | 山东大学 | 一种法匹拉韦药用结合物及在制备抗病毒药物制剂中的应用 |
US20240041866A1 (en) | 2020-12-18 | 2024-02-08 | Fujifilm Toyama Chemical Co., Ltd. | Pharmaceutical composition |
EP4265252A1 (en) | 2020-12-18 | 2023-10-25 | FUJIFILM Toyama Chemical Co., Ltd. | Pharmaceutical composition |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4590269A (en) * | 1984-03-29 | 1986-05-20 | Syntex (U.S.A.) Inc. | Process for preparing the cyclic phosphate ester of substituted 9-(1,3-dihydroxy-2-propoxymethyl)purines |
IT1207994B (it) * | 1986-01-03 | 1989-06-01 | Therapicon Srl | Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche. |
JP3845876B2 (ja) * | 1995-04-20 | 2006-11-15 | アステラス製薬株式会社 | ピラジン誘導体又はその塩を含有する安定な注射用組成物及びその製造方法 |
AU736555B2 (en) | 1998-01-07 | 2001-08-02 | Meiji Seika Pharma Co., Ltd. | A composition comprising a crystallographically stable, amphorous cephalosporin and processes for the preparation thereof |
CZ301763B6 (cs) * | 1998-08-20 | 2010-06-16 | Toyama Chemical Co., Ltd. | Protivirový prostredek a derivát dusíkatého heterocyklického karboxamidu |
ATE294185T1 (de) | 2000-02-16 | 2005-05-15 | Toyama Chemical Co Ltd | Neue pyrazin-derivate oder salze davon, pharmazeutische zusammensetzungen, die die derivate oder deren salze enthalten und intermediäre zur herstellung der derivate |
DE10161077A1 (de) * | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
PT1868581E (pt) * | 2005-04-11 | 2012-06-22 | Abbott Lab | Composições farmacêuticas que possuem perfis de dissolução melhorados para fármacos pouco solúveis |
CN101610772B (zh) | 2007-02-16 | 2013-01-16 | 富山化学工业株式会社 | 包含吡嗪衍生物的药物组合物和使用吡嗪衍生物的联合用药的方法 |
JP5174365B2 (ja) * | 2007-03-23 | 2013-04-03 | 第一三共株式会社 | キノロン含有凍結乾燥製剤の製造方法 |
RU2470924C2 (ru) * | 2007-09-27 | 2012-12-27 | Тояма Кемикал Ко., Лтд. | Органическая аминовая соль 6-фтор-3-гидрокси-2-пиразинкарбонитрила и способ ее получения |
CN102348458B (zh) | 2009-03-13 | 2013-11-06 | 富山化学工业株式会社 | 含有6-氟-3-羟基-2-吡嗪甲酰胺的片剂和粒状粉剂 |
JPWO2012043700A1 (ja) | 2010-09-30 | 2014-02-24 | 富山化学工業株式会社 | 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミドのナトリウム塩 |
-
2011
- 2011-09-29 EP EP11829249.9A patent/EP2623497B1/en active Active
- 2011-09-29 PL PL11829249T patent/PL2623497T3/pl unknown
- 2011-09-29 SI SI201130754T patent/SI2623497T1/sl unknown
- 2011-09-29 ES ES11829249.9T patent/ES2561878T3/es active Active
- 2011-09-29 SG SG2013023353A patent/SG188662A1/en unknown
- 2011-09-29 WO PCT/JP2011/072329 patent/WO2012043696A1/ja active Application Filing
- 2011-09-29 JP JP2012536534A patent/JP5936546B2/ja active Active
- 2011-09-29 HU HUE11829249A patent/HUE026794T2/en unknown
- 2011-09-29 RS RS20160178A patent/RS54642B1/en unknown
- 2011-09-29 US US13/877,037 patent/US20130217708A1/en not_active Abandoned
- 2011-09-29 MY MYPI2013001091A patent/MY161757A/en unknown
- 2011-09-29 TW TW100135204A patent/TWI507397B/zh active
- 2011-09-29 CN CN201180055096.6A patent/CN103209967B/zh active Active
- 2011-09-29 DK DK11829249.9T patent/DK2623497T3/en active
-
2013
- 2013-09-02 HK HK13110206.4A patent/HK1183014A1/xx unknown
-
2014
- 2014-10-07 US US14/508,185 patent/US9090571B2/en active Active
-
2015
- 2015-06-09 US US14/734,263 patent/US20150266832A1/en not_active Abandoned
- 2015-06-15 PH PH12015501328A patent/PH12015501328A1/en unknown
-
2016
- 2016-02-23 CY CY20161100148T patent/CY1117218T1/el unknown
- 2016-03-01 HR HRP20160218T patent/HRP20160218T1/hr unknown
- 2016-06-16 SM SM201600184T patent/SMT201600184B/it unknown
Also Published As
Publication number | Publication date |
---|---|
CN103209967A (zh) | 2013-07-17 |
SMT201600184B (it) | 2016-08-31 |
HUE026794T2 (en) | 2016-07-28 |
RS54642B1 (en) | 2016-08-31 |
US20150266832A1 (en) | 2015-09-24 |
SI2623497T1 (sl) | 2016-04-29 |
US9090571B2 (en) | 2015-07-28 |
SG188662A1 (en) | 2013-05-31 |
ES2561878T3 (es) | 2016-03-01 |
CN103209967B (zh) | 2015-04-08 |
DK2623497T3 (en) | 2016-03-21 |
EP2623497A1 (en) | 2013-08-07 |
JP5936546B2 (ja) | 2016-06-22 |
EP2623497A4 (en) | 2014-03-26 |
PH12015501328B1 (en) | 2015-09-21 |
CY1117218T1 (el) | 2017-04-05 |
JPWO2012043696A1 (ja) | 2014-02-24 |
WO2012043696A1 (ja) | 2012-04-05 |
MY161757A (en) | 2017-05-15 |
TW201217343A (en) | 2012-05-01 |
EP2623497B1 (en) | 2016-01-20 |
US20150031885A1 (en) | 2015-01-29 |
US20130217708A1 (en) | 2013-08-22 |
TWI507397B (zh) | 2015-11-11 |
PH12015501328A1 (en) | 2015-09-21 |
HRP20160218T1 (hr) | 2016-03-25 |
HK1183014A1 (en) | 2013-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1183014A1 (en) | Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2- | |
IL259958B (en) | Heterocyclic glutaminase inhibitors | |
HK1243417A1 (zh) | 吡啶酮和氮雜吡啶酮化合物及使用方法 | |
HK1183015A1 (en) | Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2- | |
IL237581B (en) | Derivatives of 6-oxo-pyrazinopyrrolopyrimidines | |
ZA201303793B (en) | Substituted quinoline compounds and methods of use | |
HK1178149A1 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4--- | |
ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
EP2772483A4 (en) | 4-AMINOCARBAZOLE COMPOUND AND USE THEREOF | |
EP2663565A4 (en) | HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF | |
AP3268A (en) | Co-crystals and salts of CCR3-inhibitors | |
EP2635587A4 (en) | NOVEL 6-ARYLAMINOPYRIDONECARBOXAMIDES AS MEK INHIBITORS | |
ZA201206456B (en) | Uses of dgati inhibitors | |
EP2625176A4 (en) | SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS | |
GB201111396D0 (en) | Monitoring of livestock | |
ZA201209666B (en) | Salts and polymorhs of dexrabeprazole | |
EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
EP2783690A4 (en) | NEW USE OF NEOHESPERIDINE | |
HK1160777A1 (en) | Novel use of neohesperidoside | |
IL243320A0 (en) | Intermediates of teroarylpiperidine and piperazine derivatives | |
HU1000688D0 (en) | Use of trifluoro-phal |